GAVI Alliance supports pneumococcal and rotavirus studies

Two GAVI Alliance supported studies were released on Tuesday regarding pneumococcal disease and rotavirus, which are two leading causes of childhood mortality.

Study results for pneumococcal conjugate vaccine dosing schedules showed that PCV is effective in three different schedules.

Researchers studied approximately 13,000 articles and 14 databases containing studies from 1994-2010 to evaluate the variety of outcomes for three vaccination schedules. They found subtle differences resulted from the schedules, but all three schedules were successful in reducing pneumococcal disease.

Researchers said that no matter the schedule used, a high level of vaccine coverage was integral to continued reduction of the disease.

A study on rotavirus burden in Africa revealed that surveillance is vital to successful and continued integration of the rotavirus vaccine.

The study incorporated data from more than 42,000 children under 5 years of age in 20 countries who were hospitalized for acute diarrhea between 2006 and 2012. Approximately 41 percent of these cases tested positive for rotavirus.

Researchers said the results indicate that surveillance will enable benchmarks to be set in order to monitor progress in the future. They encouraged forming networks in Africa and other regions to help provide surveillance.

GAVI said it has provided assistance to the World Health Organization to build networks such as the Rotavirus Surveillance Network.

Both studies were published in the Pediatric Infectious Disease Journal.